Funding for this research was provided by:
National Natural Science Foundation of China (No. 81272371)
Henan Programs for Science and Technology Development (No. 212102310134)
the National Science and Technology Major Project of China (No. 2018ZX10302205)
Zhengzhou Major Project for Collaborative Innovation (No. 18XTZX12007)
the Youth Innovation Fund of The First Affiliated Hospital of Zhengzhou University
Received: 24 February 2021
Accepted: 11 July 2021
First Online: 16 July 2021
: The study was approved by the Institutional Review Board of the First Affiliated Hospital of Zhengzhou University. All patients provided informed written consent for these genomic analyses.
: Informed consent was obtained from all individual participants included in the study, giving their authorization to access their clinical information and tumor samples for research purpose.
: Hui Li and Xiaoxing Su are the employees of Berry Oncology Corporation. All other authors declare no conflict of interests.